A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients (Accordance)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02605434|
Recruitment Status : Unknown
Verified April 2018 by Intec Pharma Ltd..
Recruitment status was: Active, not recruiting
First Posted : November 16, 2015
Last Update Posted : August 8, 2019
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Parkinson's Disease||Drug: Accordion Pill™ Carbidopa/Levodopa Drug: Sinemet® Drug: Placebo -AP-CD/LD Drug: Placebo- Sinemet||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||420 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Phase 3 Multicenter Randomized Double-Blind, Double-dummy, Active-Controlled Study Comparing Efficacy/Safety of Gastric-retentive, Controlled-release Accordion Pill Carbidopa/Levodopa to Immediate Release in Fluctuating Parkinson's Patients|
|Study Start Date :||March 2016|
|Actual Primary Completion Date :||July 2019|
|Estimated Study Completion Date :||December 2019|
Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d and Placebo IR Carbidopa/ levodopa
Drug: Accordion Pill™ Carbidopa/Levodopa
AP-CD/LD capsule containing 50 mg carbidopa with 400 mg or 500 mg levodopa administered orally twice or 3 times a day
Other Name: AP-CD/LD
Drug: Placebo -AP-CD/LD
Placebo for AP-CD/LD capsule
Active Comparator: SINEMET®
IR Carbidopa/ levodopa tablets 25/100 mg at least 4 times a day and placebo AP-CD/LD
Sinemet® tables containing carbidopa and levodopa 25/100 mg will be administered orally at least 4 times a day according to patients need
Other Name: IR Carbidopa/Levodopa
Drug: Placebo- Sinemet
Placebo for Sinemet tables
- Change from Baseline through study completion, an average of 27 weeks, in the percentage of daily "Off time" during waking hours [ Time Frame: Baseline through study completion, an average of 27 weeks ]Change from Baseline through study completion, an average of 27 weeks, in the percentage of daily "Off time" during waking hours based on Hauser Home Diary assessments; Total number of "Off " hours normalized to a 16- hour waking day will also be calculated but only a single p-value applicable to both the percentage and hours will be reported.
- Change from Baseline through study completion, an average of 27 weeks, in "On time" without troublesome dyskinesia during waking hours [ Time Frame: Baseline through study completion, an average of 27 weeks ]
- Change in the number of total daily LD doses from Baseline through study completion, an average of 27 weeks (hours) [ Time Frame: Baseline through study completion, an average of 27 weeks ]
- CGI-I through study completion, an average of 27 weeks, as recorded by physician & patient [ Time Frame: Baseline through through study completion, an average of 27 weeks, ]
- Change from Baseline through study completion, an average of 27 weeks, in total UPDRS Score (Sum of Parts I-III) [ Time Frame: Baseline through study completion, an average of 27 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||30 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Main Inclusion Criteria:
- Subjects must be approved for suitability by an Enrollment Approval Committee
- Able and willing to give written (signed and dated) informed consent and adhere to visit schedule and available to complete the study
- Men or women 30 years of age and higher at initial screening assessment. (For the 100 subjects who enter the Gastroscopy sub study, the age limits are 30-80 years of age, inclusive, at initial screening assessment)
- Diagnosed with Parkinson's disease, consistent with UK brain bank criteria
- Has a good response to Levodopa and is taking at least 4 doses of a Levodopa containing medication (or 3 doses of Rytary) per day during waking hours (not including nighttime long acting levodopa) at a stable dose for at least 28 days prior to initial screening assessment
- Other Anti-PD treatment (such as dopamine agonists, selective MAO-B inhibitors, anticholinergic agents or Amantadine) are permitted if stable for at least 28 days prior to study entry and provided they are not anticipated to be changed during the course of the study
- Total LD immediate release daily dose of 400 mg to 1300 mg or equivalent prior to initial screening assessment. Specifically for Rytary, doses up to 1755 mg daily are acceptable.
Able to complete a Hauser Home Diary and can tell the difference between "On" and "Off" time
- Achieved at least 75% diary concordance with an approved site rater in a 4-hour training session including at least one "Off time" assessment
- Returned a valid 2-day practice diary after training has been completed.
- At least 2.5 hours "Off time" per day during waking hours on Screening 2-day Practice Hauser Home Diary (morning akinesia should be incorporated into the total "Off time" assessment).
- Other than PD, the subject is in satisfactory health, as assessed by physical examination and screening tests. No clinically significant medical, psychiatric or laboratory abnormality that could compromise safety or interfere with study procedures in the opinion of either the investigator or the Enrollment Approval Committee/Sponsor.
- Living in an area that is within 3 hours driving distance from the study site or is willing to stay in such a place the night before each study visit
Main Exclusion Criteria:
- Participation in another drug clinical trial within 28 days prior to initial screening assessment (calculated from the previous study's last dosing date)
- Atypical Parkinsonism (subjects with Parkinsonian features caused by disorder such as multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies or multiple brain infarcts)
- Clinically significant cardiac, pulmonary, hepatic or renal disease or other condition or any major complication/illness which contraindicates his/her participation in the opinion of either the investigator or the Enrollment Approval Committee/Sponsor.
- Severe dyskinesia in the opinion of either the investigator or the Enrollment Approval Committee.
- Treatment with non-selective monoamine oxidase (MAO) inhibitors during the last 28 days prior to initial screening assessment or planning to take during study participation
- Previous or planned neurosurgical treatment for Parkinson's Disease (e.g., procedures including ablation or deep brain stimulation) during the course of the study
- Significant cognitive impairment as defined by the Mini-Mental State Examination (MMSE) score < 26.
- Clinically significant psychiatric illness, including major depression (Hamilton Depression Rating Scale-17 ≥14). Subjects with a lifetime history of suicidal attempt (including an active attempt, interrupted attempt or aborted attempt)
- Current or previous treatment for more than 1 month within the past 2 years with any neuroleptic drug (antipsychotic) or any other drug with anti-dopaminergic properties (e.g. metoclopramide, domperidone)
- Currently experiencing or any known history of psychosis or delusions within 2 years prior to Screening.
- Known history of substance abuse within the past 2 years
- Moderate or greater level of alcohol consumption
- Unable to swallow large pills (e.g., large vitamin pills)
- History of Melanoma or suspicious skin lesion which could be a Melanoma
- Narrow-angle Glaucoma
- History of small bowel or gastric surgery (Including PEG-J placement for Duopa/Duodopa) or bowel obstruction, diagnosis of small bowel narrowing, diagnosis of Crohn's disease, or frequent nausea or emesis, regardless of etiology, (Previous appendectomy or hernioplasty will not be exclusionary).
- Active peptic ulcer disease or a history of peptic ulcer or upper GI bleeding
- Regular use of opioids (Intermittent opioid use is not exclusionary)
- Symptomatic gastroparesis with frequent vomiting (at least once a week)
- Concomitant use of NSAIDs and oral steroids within the past 28 days
- Allergy to the study drug or any of its excipients, or to Yellow Dye #5 (tartrazine)
- Women who are pregnant or nursing. Women of childbearing potential who are not willing to use a medically acceptable method of contraception.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02605434
|Principal Investigator:||Peter A LeWitt, MD||Henry Ford Hospital - West Bloomfield|
|Responsible Party:||Intec Pharma Ltd.|
|Other Study ID Numbers:||
IN 11 004
|First Posted:||November 16, 2015 Key Record Dates|
|Last Update Posted:||August 8, 2019|
|Last Verified:||April 2018|
Fluctuating Parkinson's Disease
Advanced Parkinson's Disease
Basal Ganglia Diseases
Central Nervous System Diseases
Nervous System Diseases
Carbidopa, levodopa drug combination
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Aromatic Amino Acid Decarboxylase Inhibitors